NCT04739046 is a Phase 2 clinical trial of Theragene arm in Pancreas Cancer, sponsored by Seoul National University Bundang Hospital.

Who is sponsoring NCT04739046?

NCT04739046 is sponsored by Seoul National University Bundang Hospital.

What drugs are being tested in NCT04739046?

Interventions in NCT04739046: Theragene arm.

What condition does NCT04739046 study?

NCT04739046 studies Pancreas Cancer.

Is NCT04739046 still recruiting?

NCT04739046 is currently status unknown. Last updated 17 March 2021.

Last reviewed 2021-03-17 · How we verify

NCT04739046

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy

Status unknown Phase 2 Last updated 17 March 2021

What this trial tests

Phase 2 trial testing Theragene arm in Pancreas Cancer in 12 participants. Status unknown.

Timeline

1 February 2021

Primary endpoint
1 August 2022

1 February 2024

Quick facts

Lead sponsor	Seoul National University Bundang Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	1 February 2021
Primary completion	1 August 2022
Estimated completion	1 February 2024
Sites	1 location across South Korea

Drugs / interventions tested

Theragene arm — full drug profile →

Conditions studied

Pancreas Cancer — all drugs for Pancreas Cancer →

Sponsor

Seoul National University Bundang Hospital

Who can join

Adults 19 to 75, any sex, with Pancreas Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Replication-competent Adenovirus-mediated Double Suicide Gene Therapy (Theragene®,Ad5-yCD/mutTKSR39rep-ADP) showed safety and anti-cancer effect in patients with pancreatic cancer in phase I study. From the experience of phase I study, the safety and efficacy of combination with standard chemotherapy and radiation therapy with Theragene treatment will be assessed in this study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Viral vector-based gene therapies in the clinic.
Zhao Z, Anselmo AC, Mitragotri S. · · 2022 · cited 171× · PMID 35079633 · DOI 10.1002/btm2.10258
Evolving Horizons: Adenovirus Vectors' Timeless Influence on Cancer, Gene Therapy and Vaccines.
Trivedi PD, Byrne BJ, Corti M. · · 2023 · cited 22× · PMID 38140619 · DOI 10.3390/v15122378
Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications.
Scarsella L, Ehrke-Schulz E, Paulussen M, Thal SC, et al · · 2024 · cited 17× · PMID 38543743 · DOI 10.3390/v16030377
Oncolytic Adenoviruses Armed with Co-Stimulatory Molecules for Cancer Treatment.
Gryciuk A, Rogalska M, Baran J, Kuryk L, et al · · 2023 · cited 13× · PMID 37046608 · DOI 10.3390/cancers15071947
The Clinical Advances of Oncolytic Viruses in Cancer Immunotherapy.
Zolaly MA, Mahallawi W, Khawaji ZY, Alahmadi MA. · · 2023 · cited 10× · PMID 37485097 · DOI 10.7759/cureus.40742
Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic Cancer.
Kuo KK, Hsiao PJ, Chang WT, Chuang SC, et al · · 2021 · cited 10× · PMID 34359820 · DOI 10.3390/cancers13153920
Therapeutic potential of gene therapy for gastrointestinal diseases: Advancements and future perspectives.
Yue NN, Xu HM, Xu J, Zhu MZ, et al · · 2023 · cited 7× · PMID 37663132 · DOI 10.1016/j.omto.2023.08.007
Research and Clinical Progress of Therapeutic Tumor Vaccines.
Dong C, Li Z, Tan D, Sun H, et al · · 2025 · cited 3× · PMID 40733649 · DOI 10.3390/vaccines13070672

Verify or expand the search:

Other recruiting trials for Pancreas Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07230509 — Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate · Phase 2 · recruiting
NCT06926075 — Early Phase Study of KESONOTIDE™in Participants With Solid Tumours · Phase 1, PHASE2 · recruiting
NCT07179692 — CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors · Phase 1 · recruiting
NCT07132541 — Saleh's Technique for Pancreaticojejunostomy (Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate) · Phase 1 · recruiting

Other Seoul National University Bundang Hospital trials

Trials by the same sponsor.

NCT07459725 — Comparison of EEG-Timed vs. Repetitive Robot Therapy for Chronic Stroke · NA · not yet recruiting
NCT07455279 — Surface Electromyographic Analysis of Normal Swallowing in Children: An Exploratory Study · not yet recruiting
NCT07477574 — Muscle-Specific Multimodal AI for Sarcopenia Diagnosis · NA · not yet recruiting
NCT07505290 — Efficacy of the Korean PEERS® for Preschoolers (PEERS®-PS-K) Social Skills Intervention: A Randomized Controlled Trial f · NA · active not recruiting
NCT07305662 — Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGU · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04739046 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Bundang Hospital
Last refreshed: 17 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04739046.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing